NEWS
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer patients, showing a median PFS of 4.1 months, nearly double the rate of similar studies. Dr. Saranya Chumsri and Dr. Carmen Calfa highlighted the potential for Bria-IMT™ to address unmet medical needs in advanced breast cancer. Further, BriaCell's pivotal Phase 3 study will compare Bria-IMT™ with Treatment of Physician's Choice (TPC).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1083Followers
68Following
7471Visitors
Follow
Mcsnacks H Tupack : Stock offering on file